Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

461.66 +4.73 (+1.04%)

Streaming Delayed Price Updated: 3:53 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

Today 16:05 EDT

From Medpace Holdings, Inc.

Via Business Wire

Q4 Earnings Highs And Lows: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

March 22, 2026

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind...

Via StockStory

Medpace Holdings Inc (NASDAQ:MEDP) Passes Key CAN SLIM Growth Filter Amid Technical Caution ↗

March 09, 2026

Via Chartmill

2 Healthcare Stocks with Exciting Potential and 1 We Avoid

March 09, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

Medpace Holdings Inc (NASDAQ:MEDP) Stock Falls Despite Strong Q4 Earnings Beat ↗

February 09, 2026

Via Chartmill

3 Profitable Stocks for Long-Term Investors

March 05, 2026

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance pro...

Via StockStory

Medpace (NASDAQ:MEDP): Strongest Q4 Results from the Drug Development Inputs & Services Group

March 01, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q4,...

Via StockStory

Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Topics Government World Trade

Investment Manager Bets Big on Varonis Stock, According to Recent SEC Filing ↗

February 23, 2026

Varonis Systems provides data security and analytics software to global enterprises, helping organizations manage access and compliance.

Via The Motley Fool

Topics Regulatory Compliance

American Capital Management Doubles Down on Novanta Stock, According to Latest SEC Filing ↗

February 19, 2026

Novanta delivers advanced photonics and precision motion components for medical and industrial OEMs worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Bets on Proto Labs Stock, According to Recent SEC Filing ↗

February 19, 2026

Proto Labs provides rapid digital manufacturing for engineers and product developers, using an e-commerce-driven, technology-enabled model.

Via The Motley Fool

Topics Regulatory Compliance

MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm

February 19, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

6 Stock Ideas for the Next 5 Years ↗

February 17, 2026

Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks!

Via The Motley Fool

Topics Artificial Intelligence

Why Big Stock Swings Like Medpace's 55% Jump Usually Have Clear Causes--Not Market Madness ↗

February 16, 2026

Understanding the real drivers behind dramatic stock swings can help investors avoid costly mistakes and spot opportunities hidden beneath the headlines.

Via The Motley Fool

The 5 Most Interesting Analyst Questions From Medpace’s Q4 Earnings Call

February 16, 2026

Medpace’s fourth quarter was marked by robust top-line growth and a significant year-over-year increase in revenue, but the market responded negatively, likely due to rising cancellations and margin...

Via StockStory

Topics Earnings

The Clinical Crisis: A Deep-Dive Into ICON plc (ICLR) Amidst a Transformational Storm

February 12, 2026

Date: February 12, 2026 Introduction ICON plc (NASDAQ: ICLR) currently finds itself at a pivotal and precarious crossroads. As the world’s second-largest Clinical Research Organization (CRO), the...

Via Finterra

Topics Artificial Intelligence Fraud Lawsuit

1 Cash-Producing Stock with Competitive Advantages and 2 That Underwhelm

February 11, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth

February 10, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 32% year on year to $708.5 million. The company expects the...

Via StockStory

Topics Artificial Intelligence

Medpace (MEDP) Q4 2025 Earnings Call Transcript ↗

February 10, 2026

Medpace (MEDP) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025

February 09, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 32% year on year to $708.5 million. The company expects...

Via StockStory

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

February 09, 2026

From Medpace Holdings, Inc.

Via Business Wire

Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow

February 07, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results this Monday afternoon. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

3 Market-Beating Stocks to Consider Right Now

February 05, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

Via StockStory

1 Volatile Stock with Solid Fundamentals and 2 We Avoid

January 28, 2026

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

Topics Economy Supply Chain

2 Cash-Heavy Stocks with Promising Prospects and 1 We Find Risky

January 18, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?

January 15, 2026

What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, reaching $617.27 per share. This was partly due to its solid quarterly...

Via StockStory

Topics Supply Chain

2 Healthcare Stocks to Keep an Eye On and 1 We Ignore

January 12, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only...

Via StockStory

Topics Stocks

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026

January 05, 2026

From Medpace Holdings, Inc.

Via Business Wire

1 Mid-Cap Stock with Competitive Advantages and 2 We Avoid

January 04, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

December 31, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.